Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences submitted its audited standalone and consolidated results for Q4 and FY25. Revenue from operations for the year slipped slightly to Rs 1,66,997 lakhs from Rs 1,68,409 lakhs in FY24, a decline of around 0.8%. The company swung to a net loss of Rs 11,368 lakhs for FY25 versus a profit of Rs 500 lakhs last year, with EPS turning negative at Rs (5.07) versus Rs 0.22. The Q4 loss alone was Rs 13,009 lakhs, driven mainly by a one-time write-down of non-current inventory from Rs 17,733 lakhs to Rs 5,061 lakhs (about a Rs 12,672 lakh hit) based on ageing and realizable value. The auditor issued an unmodified opinion but flagged this write-down as an Emphasis of Matter. Operating cash flow remained positive at Rs 16,944 lakhs, and short-term borrowings rose while long-term debt declined.
Shareholders should brace for negative sentiment as the company reported a full-year loss for the first time in recent memory, mainly due to the large non-cash inventory write-down. However, the write-down removes a long-pending overhang, and the company remains operational with positive operating cash flow. Additionally, the Rs 1.53 lakh fine paid to NSE and BSE each for delayed filing is a minor governance red flag but unlikely to materially affect the stock.